These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta. Aström E; Magnusson P; Eksborg S; Söderhäll S Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960 [TBL] [Abstract][Full Text] [Related]
3. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta. Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750 [No Abstract] [Full Text] [Related]
4. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. DiMeglio LA; Ford L; McClintock C; Peacock M Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028 [TBL] [Abstract][Full Text] [Related]
6. Intravenous pamidronate in osteogenesis imperfecta type VII. Cheung MS; Glorieux FH; Rauch F Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231 [TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. Land C; Rauch F; Montpetit K; Ruck-Gibis J; Glorieux FH J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404 [TBL] [Abstract][Full Text] [Related]
8. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424 [TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486 [TBL] [Abstract][Full Text] [Related]
10. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Rauch F; Travers R; Plotkin H; Glorieux FH J Clin Invest; 2002 Nov; 110(9):1293-9. PubMed ID: 12417568 [TBL] [Abstract][Full Text] [Related]
11. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Land C; Rauch F; Travers R; Glorieux FH Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117 [TBL] [Abstract][Full Text] [Related]
13. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome. Bajpai A; Kabra M; Gupta N; Sharda S; Ghosh M J Pediatr Orthop; 2007 Mar; 27(2):225-7. PubMed ID: 17314651 [TBL] [Abstract][Full Text] [Related]
14. Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report. Olson JA J Pediatr Rehabil Med; 2014; 7(2):155-8. PubMed ID: 25096867 [TBL] [Abstract][Full Text] [Related]
15. Two doses of pamidronate in infants with osteogenesis imperfecta. Senthilnathan S; Walker E; Bishop NJ Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634 [TBL] [Abstract][Full Text] [Related]
16. [Osteogenesis imperfecta and bisphosphonates]. Forin V Arch Pediatr; 2005 Jun; 12(6):688-90. PubMed ID: 15904772 [No Abstract] [Full Text] [Related]
17. Alendronate treatment in children with osteogenesis imperfecta. Akcay T; Turan S; Guran T; Bereket A Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788 [TBL] [Abstract][Full Text] [Related]
18. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta. Gökşen D; Coker M; Darcan S; Köse T; Kara S Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111 [TBL] [Abstract][Full Text] [Related]